Moderna AI Cancer Trial Success Sparks $44B Market Value Jump
imjustnewatai · x · 2026-08-20
Moderna announced that its AI-personalized cancer therapy, intismeran, combined with Keytruda, met Phase 3 endpoints by significantly reducing melanoma recurrence. The therapy uses fully integrated AI algorithms to design unique mRNA sequences for each patient based on post-surgery tumor sequencing, effectively creating a different drug version for every individual. This news sent Moderna's market value up by roughly $44 billion in a single day.
Related event: Moderna's AI-Designed Personalized mRNA Cancer Vaccine Wins Phase III(23 posts)→
More from Apps
- Grok Bot Directory Launched with 170+ Ready-to-Use Bots, Open Source — heypearlai · 2026-08-20
- Runway launches Model Router: Auto-selects best model per API call — umpherj · 2026-08-20
- Tool exports AI chats to Markdown for cross-platform context migration — DaikonCharacter6259 · 2026-08-20
- Show HN: Why You Lost – a Dota 2 post-match autopsy tool — gnusi · 2026-08-20
- Indie Dev Ships First Creator Payout for SaaS Matching Video Creators and Brands — tibo_maker · 2026-08-20
- Replit users report checkpoint creation failure — Kyrannio · 2026-08-20